Nephrology

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, SLE, PSF, FDA, Insurance, American College, EGFR, U.S.–Canada Team Tournament (Go), Conversation, SG, EDGAR, SEDAR, American Society of Nephrology, AURORA, Nephrology, Lupus, Persistent environment, EC, Glomerular filtration rate, R, Society, Arthritis & Rheumatology, Bank statement, Growth, Risk, Marketing, Webcast, Analysis, Healthcare Improvement Scotland, American College of Rheumatology, Safety, LN, Investment, Management, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Rheumatology, Cryptocurrency, Pharmaceutical industry, Rare-earth element, Aurinia

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the three and nine months ended September 30, 2023.
  • Total net revenue was $54.5 million for the three months ended September 30, 2023 and $55.8 million for the same period in 2022.
  • Financial Results for the Three and Nine Months Ended September 30, 2023
    Total net revenue was $54.5 million and $55.8 million for the three months ended September 30, 2023 and September 30, 2022, respectively.
  • Aurinia will host a conference call and webcast to discuss the quarter ended September 30, 2023 financial results today, Thursday, November 2, 2023 at 8:30 a.m.

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Leicester, Survival, FRCP, ALPN, GN, EGFR, Biomarker, Fig, Nephrology, PMN, MD, Inflammation, Cytokine, Doctor of Philosophy, Glomerular filtration rate, Immunoglobulin A, American Society of Nephrology, Multimedia, Society, BAFF, Glossary of education terms (G–L), Disease, Barratt, ASN, Webcast, Emory University School of Medicine, University, Immunoglobulin G, Autoimmunity, Glomerulonephritis, Patient, Infection, Vaccine, Sewage treatment, Pharmaceutical industry, Research, IgA nephropathy, Proteinuria, Alpine, Medicine, UPCR

RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.

Key Points: 
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.
  • A higher dose of povetacicept, 240 mg SC every four weeks, continues to enroll, with initial data expected in 1H 2024.
  • A higher dose of povetacicept 240 mg every four weeks is currently being explored and will be of great interest.
  • “We eagerly await the initial data from the next 240 mg dose level in the first half of 2024.

New Data Insights Unveiled at ASN Kidney Week 2023 Point to the Impact of the Tablo® Hemodialysis System on Equitable Kidney Care

Retrieved on: 
Wednesday, November 1, 2023
Health, Medical Devices, Health Technology, Managed Care, General Health, Clinical Trials, Biotechnology, Patient, Medicare, Experiment (probability theory), Learnability, Medicine, HHD, MD, Nephrology, Research, Society, Dialysis, ASN, Abstract, Pythagorean Method of Memorization, Kidney, PRO, Insomnia, Health insurance, Pharmaceutical industry, Nursing, Medical device, Outset Contemporary Art Fund, Tablo

The five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5.

Key Points: 
  • The five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5.
  • The annual event gathers more than 10,000 kidney care professionals from across the globe, offering a forum to delve into the latest advancements in nephrology and to collaborate on kidney care innovation.
  • "The research abstracts we're presenting at ASN Kidney Week are more than data points; they are a testament to Tablo's adaptability, versatility and its profound impact on equitable healthcare,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical.
  • Attendees are invited to visit the Outset booth (#1117) during the ASN meeting for more information.

AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease

Retrieved on: 
Tuesday, October 31, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Principal, Ruijin Hospital, Fabry disease, Enzyme replacement therapy, GCS, Pharmacokinetics, Strong, Nephrology, Safety, Therapy, Patient, Pharmaceutical industry

AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.

Key Points: 
  • AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
  • AL01211 is a novel, oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor being developed to treat glycosphingolipid storage diseases, including Fabry Disease and Type 1 Gaucher Disease.
  • “We are delighted to initiate enrollment in our Phase 2 study for patients with Fabry disease at one of the most renowned academic centers in China,” said Dr. Pedro Huertas, M.D.
  • I am excited to have dosed the first patient in the company’s Phase 2 program for AL01211 and am dedicated to maintaining the highest standards throughout the trial.”

AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)

Retrieved on: 
Thursday, November 2, 2023
Week, University of Colorado, Kidney, Health, Blood pressure, Prevalence, Nephrology, Society, Chronic kidney disease, University of Colorado Denver, Division, Amgen, Methotrexate, University, AMGN, CKD, Patient, Randomized controlled trial, MIRROR, Gout, Pharmaceutical industry, Hypertension

The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.

Key Points: 
  • The data will be presented at the American Society of Nephrology Kidney Week, taking place Nov. 2-5, in Philadelphia.
  • "Recognizing the high prevalence of hypertension among these patients, we're excited to present data that offers new insight into the potential role of urate reduction with KRYSTEXXA with methotrexate in regulating blood pressure."
  • Treatment groups had similar blood pressure prior to treatment.
  • "These new data add to prior studies and further support the potential role that both KRYSTEXXA urate-lowering and methotrexate administration played in the blood pressure changes observed."

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Kidney, Mitophagy, Trial of the century, Mission, Mitochondrion, Therapy, Treatment, DUB, Acute kidney injury, AKI, Society, Risk, Master of Science, Pharmacology, Nephrology, Safety, Patient, American Society of Nephrology, MS, Simulation, Pharmaceutical industry

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

Key Points: 
  • CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
  • Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
  • The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
  • A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.

Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Kidney, Mitophagy, Trial of the century, Mission, Mitochondrion, Therapy, Treatment, DUB, Acute kidney injury, AKI, Society, Risk, Master of Science, Pharmacology, Nephrology, Safety, Patient, American Society of Nephrology, MS, Simulation, Pharmaceutical industry

CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.

Key Points: 
  • CAMBRIDGE, England, Nov. 2, 2023 /PRNewswire/ -- Mission Therapeutics ("Mission"), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that it will present an oral abstract on its experimental drug candidate MTX652 at the American Society of Nephrology's Kidney Week in Philadelphia, from 2-5 November 2023.
  • Mission Therapeutics is a world leader in discovering and developing novel therapeutics which promote the removal of dysfunctional mitochondria to maintain cell health and function.
  • The American Society of Nephrology is a major organization working toward a goal of a world without kidney diseases and we are excited to have the opportunity to share our progress at this important conference.
  • A Phase II trial of MTX652 in patients at risk of acute kidney injury following cardiac surgery is planned to start in Q1 2024.

Dr. Verna Yiu appointed to EPCOR Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
Knowledge, MedlinePlus, Faculty, Royal College of Physicians and Surgeons of Canada, Health, Surgeon, University, AB, Alberta Health Services, Stollery Children's Hospital, EPCOR, Royal college, Medicine, Physician, Executive, Teaching, Public, Nephrology, Patient, Hospital, International Pediatric Nephrology Association, Pediatrics, Nursing

EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.

Key Points: 
  • EDMONTON, AB, Nov. 1, 2023 /CNW/ - EPCOR Utilities Inc. (EPCOR) is pleased to announce the appointment of Dr. Verna Yiu to its Board of Directors.
  • "Dr. Yiu is highly recognized for her dedication and leadership in the fields of medicine and academia, as well as for her commitment to advancing the health and outlook of the patients in her care and the communities she serves," said Janice G. Rennie, EPCOR Board Chair.
  • We are fortunate and pleased to welcome her to our Board."
  • In addition to previous faculty leadership roles at the University of Alberta, Dr. Yiu served as the Executive Vice-President and Chief Medical Officer (2012-2016) and then as the President and CEO (2016-2022) of Alberta Health Services.

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Tuesday, October 31, 2023
Kidney, Frankfurt Stock Exchange, Patient, Hemofiltration, Research, FME, Intelligence, III, HDF, Assessment of kidney function, AVF, Big data, Fatigue, HD, American Society of Nephrology, Saskatchewan River Sturgeon Management Board, Arteriovenous fistula, FX, Health, Society, Artificial intelligence, Dialysis, PO4, PSM, COVID-19, ASN, Machine learning, Congress, Fresenius Medical Care, FKC, RBV, Creatinine, Scientific Committee on Oceanic Research, FMS, Peritoneum, IDS, Data science, Pharmaceutical industry, Medical device, Hemodialysis, Nephrology

Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.

Key Points: 
  • Fresenius Medical Care announces presentations at the American Society of Nephrology (ASN) Kidney Week 2023.
  • Scientific and medical experts from across Fresenius Medical Care will present research related to many important topics in kidney disease care.
  • Through its network of 4,050 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 344,000 patients around the globe.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Proactive Worldwide Welcomes Two Strategic Hires to Enhance Its Competitive Intelligence Operations

Retrieved on: 
Monday, October 30, 2023
Knowledge, Allergy, Yoder, Avery, Intelligence, Political science, Headache, CPG, Hematology, Dermatology, Insurance industry in China, Nephrology, Customer retention, Research, Prostate, Crohn's disease, Lung, University, PWW, Asthma, Osteoporosis, Human voice, Melanoma, Alzheimer's disease, Pain, Moses Austin, Bachelor of Science in Human Biology, Bachelor of Arts in Organizational Psychology, Fortune 500, Retail, Pharmaceutical industry, Insurance

SCHAUMBURG, Ill., Oct. 30, 2023 /PRNewswire/ -- In a strategic move to accommodate the increased demand for their competitive research and analysis services, Proactive Worldwide (PWW) is thrilled to announce the onboarding of two new senior analysts, Heather Yoder and Avery Ekman. These latest hires reflect PWW's commitment to offer the finest expertise in the competitive intelligence sector.

Key Points: 
  • These latest hires reflect PWW's commitment to offer the finest expertise in the competitive intelligence sector.
  • Dr. Heather Yoder shifted from the medical field into the realm of pharmaceutical competitive intelligence.
  • Her experience spans over 10 years, with remarkable achievements in primary and secondary research, analysis, as well as project management.
  • Their combined expertise will further ensure that our clients continue to receive actionable insights and value, backed by extensive research and analysis."